The issue of human lifespan has long been a matter of controversy among scientists. In spite of the recent claim by Dong et al that human lifespan is limited to 115 years, with the mounting improvements in biotechnology and scientific understanding of aging, we may be confident that aging will slow down over the course of the current century extending human longevity much longer than 115 years.
To learn more, please visit the YouTube Help Center: https://www.youtube.com/help
An eagerly awaited and controversial clinical trial to ‘wind back the clock’ on aging cells in the eye and restore them to a more youthful state has officially begun.
This week, the United States biotechnology company Life Biosciences, Inc. announced that it had dosed its first patient with an experimental therapy designed to reverse age-related vision loss.
The ambitious idea is to turn back aging by activating three genes in retinal ganglion cells, which connect the brain to the eyes.
After outliving Booker T. Bones, their second service dog, Brenda and Brian Marquis still needed help with some of the more difficult parts of daily life.
They found Robbie, a robot that rolls out of a hallway into their living room several times a day.
“Do you want to exercise now? Please answer yes or no,” the caregiver robot asks 59-year-old Brian Marquis, who has been living with a traumatic brain injury since a 2012 car crash.
Are we on the verge of outrunning aging entirely? Renowned futurist and inventor Ray Kurzweil shares his data-driven predictions on the exponential trajectory of artificial intelligence and its near-term impact on human health.
Speaking to a Cosmos conference from his studio, Kurzweil charts the predictable, uninterrupted 80-year history of computing power from early wartime codebreaking machines to modern cloud processors. He explains why the sudden emergence of massive neural networks and \.
Aging involves a decline in physiological functions and increased disease susceptibility, with the immune system playing a pivotal role. Recent research reveals that nonimmune structural cells, such as fibroblasts, epithelial cells, and neurons, develop immune-like properties crucial for stress response and tissue integrity. However, with aging, these organized, nonimmune cells in multicellular organisms gradually lose their identity and organization. They may exhibit unicellular properties, acquire macrophage-like characteristics, or enter a state of senescence, contributing to chronic inflammation.
Two of my favorite people. Definitely worth a view if you are interested in either.
Few thinkers have shaped our understanding of the future as profoundly as Ray Kurzweil. An American inventor, computer scientist, futurist, entrepreneur, and bestselling author, Kurzweil is widely regarded as one of the most influential technological forecasters of our time. For decades, he has accurately predicted many of the innovations that now define modern life, from mobile computing and artificial intelligence to digital assistants and large language models often years before they entered the mainstream.
In this special conversation, Tony Robbins sits down with Ray Kurzweil in San Francisco to explore one of the most important questions facing humanity: What happens next?
Together, they examine the accelerating pace of artificial intelligence, the path toward Artificial General Intelligence (AGI), the rise of autonomous agents, the future of work and education, breakthroughs in healthcare and longevity, and how these technologies may transform society over the coming decade.
Kurzweil explains why his long-standing prediction of AGI by 2029 now appears increasingly conservative, why the next few years may bring more change than any period in human history, and how humanity may ultimately merge with the very technologies it creates.
Boston-based biotechnology company Life Biosciences has launched the first-in-human clinical trials of a pioneering “partial cellular reprogramming” technique designed to treat optic nerve damage caused by glaucoma and NAION. Based on previous genetic research, the therapy utilizes a modified virus to deliver three youth-restoring genes to retinal cells, aiming to reverse cellular aging while preserving their specialized functions. Addressing the critical risk of inducing cancer through uncontrolled cell division, the protocol incorporates a vital safety switch: the rejuvenating genes are only activated in the presence of the antibiotic doxycycline. The eye was strategically selected for these initial trials because its relative isolation minimizes the risk of systemic, life-threatening side effects. Involving up to 12 patients, this groundbreaking study serves as a crucial test not only for the potential restoration of vision but for the safety, viability, and future reputation of partial reprogramming as a broader anti-aging and regenerative medicine therapy.
A participant in a landmark clinical trial has been given a cellular-reprogramming treatment that aims to rejuvenate damaged cells in the eye.